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INTRODUCTION
Iron overload is common in chronically transfused thalassemia major (TM) patients. Liver iron is a surrogate for total body iron burden 1 and has been used for years to monitor chelation therapy in thalassemia patients 2 . Liver iron quantification by MRI is well validated and becoming increasingly routine at major thalassemia centers 3 . It is also now possible to directly image preclinical iron deposition in heart tissue and endocrine glands 4, 5 . Extrahepatic tissues have different kinetics of iron uptake and clearance than the liver 6,7 because they selectively, or near selectively, load circulating non-transferrinbound iron (NTBI) 8 . As a result, cardiac iron accumulation exhibits threshold behavior with respect to liver iron concentration 9 and is quite sensitive to the duration of iron chelation therapy 10 . In contrast, the liver is the dominant storage depot for transferrinmediated iron uptake and fluctuates proportionally to global iron balance 11 . As a result, cross-sectional correlations between heart and liver iron loading are poor 5, 12 and longitudinal relationships exhibit complicated, highly nonlinear behaviors 7 . More importantly, dangerous heart iron accumulation and cardiac dysfunction can occur despite apparently superb control of liver iron during prospective longitudinal evaluation 7,13 . These observations demonstrate that iron chelation therapy sufficient for neutral or negative liver iron balance may be inadequate to protect the heart in some patients.
Since the heart and pancreas predominantly load NTBI, iron burdens in these organs should be more closely correlated to one another than between the heart and the liver 8 . Recent work by Au, and by our laboratory, support this hypothesis 4, 14 . Since glucose intolerance/diabetes are common co-morbidities with cardiac dysfunction 11,15 ,
For personal use only. on October 3, 2017 . by guest www.bloodjournal.org From we postulated that pancreatic iron uptake might predict cardiac iron deposition in a clinically useful manner. To test this hypothesis, we compared pancreatic, hepatic, and cardiac iron loading in 131 patients with TM. Our objective was to determine whether pancreatic iron estimates could serve as an early warning system for cardiac iron loading, offering complementary information to the cardiac and liver iron estimates routinely obtained in these studies. Los Angeles (CCI#07-00141). Prospective pancreatic MRI data was obtained from 17 control subjects. Informed consent was obtained for these patients (CCI#2000-076).
Approval was obtained from the Children's Hospital Los Angeles institutional review board for these studies. Informed consent was provided according to the Declaration of Helsinki. 260 MRI studies suitable for analysis were identified from 131 patients (2.0 ± 1.3 exams per patient, range 1-6 exams). A study was deemed usable if it had pancreas, heart and liver iron measurements reported on the same visit; patients or exams with missing data were excluded. Since more than 70% of patients represented referrals from outside institutions and were often studied on weekends and evenings, it was not possible to obtain consistent clinical data beyond the patient age, gender, diagnosis, and type of chelation therapy.
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From All MRI studies were performed in a 1.5T General Electric CVi scanner running system 9.1. MRI methods for the liver and heart have been previously described 16, 17 . 16 . Cardiac R2*, equal to 1000/T2*, was used for all statistical comparisons because R2* is proportional to cardiac iron 18, 19 .
Since some subjects had undergone multiple examinations, all MRI values were inversely weighted by the number of exams such that each patient contributed equally to correlation and group-wise analyses. Weighted least-squares linear regression was used to assess the linear associations between HIC, pancreatic R2* and cardiac R2*. Weighted logistic regression with respect to age was performed to determine the time-varying prevalence of cardiac and pancreatic iron loading. Weighted Receiver Operator
Characteristic analysis was performed between pancreatic R2* and cardiac R2* to determine how well pancreatic iron served as a surrogate for cardiac iron deposition. The longitudinal relationship between cardiac and pancreatic R2* was determined by calculating the two point differential between the first and last study visits (delta R2* divide by delta time). Serial data was available in 43 patients with an observation interval of 2.1 ± 0.9 years (range 0.4 -3.7 years). Scatterplots and linear regression were calculated between the heart differential and pancreatic or liver differentials; no weighting was necessary since all patients contributed equally to this comparison. All statistics were performed in JMP 5.1 (SAS, Cary, NC).
RESULTS
Demographics of the study populations are summarized in Table 1 . Deferasirox and deferoxamine monotherapy predominated although a few subjects received combined therapy. Control subjects were slightly older and not ethnically matched to the patient population. HIC was not elevated in any control subject. Cardiac R2* was not measured in these subjects but was 30 ± 5 Hz in a previous cohort 20 . The pancreas R2* 95% confidence interval derived from normal controls was 28.1 Hz; 80.4% of patients had values exceeding this cutoff. Using the literature-accepted R2* cutoff of 50 Hz (T2* < 20 ms), elevated cardiac iron was observed in 37.7% of patients. Interobserver variability for pancreas R2* was 15.6% with no interobserver bias.
Pancreas R2* was weakly associated with HIC (r 2 = 0.13, P< 0.0001); results not
shown. The poor correlation results from the difference in iron uptake between the liver and endocrine glands; comparable to the relationship between the liver and the heart 7 .
However, a stronger association was observed between pancreas R2* and cardiac R2*. ROC analysis was also performed between cardiac iron and liver iron. AUROC was 0.51, which is statistically identical to random chance. No threshold was associated with increased probability of cardiac iron. Liver iron concentration demonstrated no statistically significant trend with age using either linear or logistic regression.
To determine how closely changes in cardiac iron follow changes in pancreatic iron, we plotted the differential of heart R2* against the differentials of pancreatic R2* and HIC, respectively (Figure 4) . Changes in cardiac R2* correlated with changes in pancreatic R2* (r 2 = 0.33, p< 0.0001), but were uncorrelated with changes in HIC (r 2 = 0.025, p=0.25). While the longitudinal linear correlation was slightly weaker than the cross-sectional analysis, the direction of pancreatic and cardiac changes were generally 
DISCUSSION
The primary goal of this study was to determine whether monitoring pancreatic R2* offered additional information to our routine practice of measuring HIC and cardiac R2*. A relationship between pancreatic and cardiac R2* was predictable given that both organs both take up NTBI 8 . The relatively high linear correlation in TM patients suggests a graded response in both tissues and has been reported by us and by others 4, 14 .
In the present study, the relationship was maintained across multiple time points (an average of 2 studies per patient). Proportionality was also preserved in the differential changes of heart and pancreatic iron (in 43 patients), suggesting that the kinetics of loading and unloading iron are more similar than for the liver and the heart 7 . More importantly, the pancreas appears to load iron earlier than the heart, providing an early marker of inadequate chelation regimes and a greater time window for intervention.
Based on these observations, pancreatic iron measurements provide important feedback, even when both cardiac T2* and liver iron results are available. It is a notoriously slow and difficult process to remove cardiac iron 6, 22 . If a patient with a normal cardiac T2* demonstrates a rising pancreatic R2*, it would be prudent to modify iron chelation to prospectively prevent cardiac iron accumulation rather than wait for cardiac iron to appear. Similarly, a declining pancreatic R2* consistently predicted In contrast, acquisition of liver and pancreas R2* can be obtained in 4 breath-holds and do not require special localization or gating; liver acquisition alone can be achieved in 1 breathhold. In patients who are unable to hold their breath, high quality imaging can still be collected in under 5", making it potentially possible to collect data in elementary school age children without anesthesia. This would make iron surveillance imaging safer and more palatable to parents of children in this age group. Cardiac iron deposition is rare before the age of 10 years of age in well-transfused, well-chelated TM patients 23 . The present data suggest that a quick, non-sedated abdominal examination might be able to detect children at highest risk of premature cardiac iron accumulation. Additionally, staging the abdominal and cardiac components of the examination might be particularly important in countries where scanner availability and health care resources are critically limiting. High throughput abdominal scanning might represent an attractive alternative to comprehensive examination in these environments.
The algorithm used at our institution is shown in Figure 5 . heart MRI as standard of care; transition to the low risk track occurs only if both cardiac iron is undetectable and pancreas R2* is < 100 Hz. Based upon the logistic regression relationships shown in Figure 3 , it is clear that TM patients inexorably trend to the high risk track. Nonetheless, this staged algorithm significantly decreases magnet utilization and imaging charges in our relatively young population. Savings are much higher in chronically transfused SCD patients where cardiac iron accumulation is less frequent 20 .
Prospective, multicenter studies are warranted to explore the staged algorithm further.
Iron overload in the pancreas may also have a direct impact on pancreatic function. Since this was a retrospective trial with limited clinical data, we did not know
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pancreas functional status of all of the patients. However, there were 9 patients with known diabetes, all of whom had moderate to severe pancreatic iron (>150 Hz) as well as cardiac iron (140.2 ± 77.6 Hz). Recent work by Au, et al, suggests that cardiac R2* is a better predictor of pancreatic dysfunction than pancreatic R2* 4 . Pancreatic iron deposition is an early event and many patients initially have normal glucose metrics 24 .
Over time, iron-mediated oxidative stress triggers apoptosis, volume loss, and fatty replacement, leading to pancreatic dysfunction 4, 24, 25 . Prospective, longitudinal studies are necessary to fully characterize the links between pancreatic R2* and pancreatic function;
we are currently enrolling patients in a prospective trial to assess this question.
This retrospective study had several important limitations. Since the patients were referred for MRI from multiple centers and since the study was retrospective, clinical data regarding duration and intensity of transfusions was unavailable. Iron chelation therapy varied among patients and over time, but was generally limited to deferoxamine and deferasirox therapy. The longitudinal relationships among liver, pancreas and cardiac iron may depend upon the dose, route, and type of iron chelation therapy. The pancreatic R2* measurements are more difficult than for liver or cardiac R2*. The pancreas is an irregularly structured gland and has a variable course. The splenic artery can be a useful landmark, but unavailable in splenectomized patients.
Bowel gas can artificially raise R2* values in the pancreas, but never to greater than 100Hz; this is one reason why 100Hz is a better threshold for "significant" pancreatic iron overload. In older patients and those with high iron concentrations, gland involution over time makes it harder to define gland boundaries. A few older patients also had significant fatty replacement, producing severe oscillations in the signal decay that
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From precluded R2* quantitation over the entire gland. Techniques that separate fat and water signals could be helpful in resolving this issue and are being developed for other body composition studies, but accurate pancreas R2* measurements cannot be performed in all patients. Interobserver variability was higher than described for either liver or heart and reflects the heterogeneity of pancreas shape, fatty infiltration, and susceptibility artifacts from bowel gas. Despite this measurement variability, pancreas R2* retained a high correlation with cardiac R2* and good predictive power for cardiac iron loading.
The logistic regression performed in this study strongly suggests that the pancreas "leads" the heart in iron loading. However, it was primarily a cross-sectional comparison, spanning only a few years of observation. To fully garner the temporal association between pancreatic and cardiac iron in individual patients would require decades of observation. Nonetheless, the cross-sectional relationship is far too powerful to represent random chance. Random fluctuations and differences in iron loading/unloading rates tend to disrupt cross-sectional relationships, not reinforce them 7 . Despite all of the present limitations, pancreas R2* measurements in children and young adults are relatively straightforward to incorporate in clinical practice as prospective markers of cardiac iron risk. The proposed staged algorithm may allow earlier MRI screening for centers unable or unwilling to sedate small children. Staging would reduce costs and magnet demand.
Further work is necessary to determine the functional significance of pancreatic iron loading to glucose and insulin regulation. risk. Low risk patients will only receive an abdominal MRI (continue in the low risk track) until their pancreas R2* is greater than 100 Hz. If a pancreatic R2* > 100 Hz is measured upon abdominal examination, the patient will have a complete cardiac MRI evaluation and they will transition to the high risk track. A patient in the high risk track receives both liver and heart MRI routinely until cardiac R2* is < 50 Hz and pancreas R2* is < 100 Hz, when they will be moved into the low risk track.
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